Author: Kathryn Atkins

Reductive Carboxylation of Glutamine as a Potential Target in AML

January 16, 2024

“Identification and validation of novel and targetable metabolic weaknesses in AML is ongoing.” BUFFALO, NY- January 16, 2024 – A new editorial paper was published in Oncotarget's Volume 14 on… read more

Oncotarget

One More Step Toward Treatment of PARP Inhibitor-resistant Ovarian Cancers

January 10, 2024

“This initiative is geared towards identifying additional biomarkers that can aid in selecting the most appropriate treatments for ovarian cancer.” BUFFALO, NY- January 10, 2024 – A new editorial paper… read more

Figure 9: One-step SARS-COv2 genome assembly in yeast S. cerevisiae using transformation-associated recombination (TAR) in yeast

Oncotarget

Transformation-associated Recombination (TAR) Cloning and Its Applications

January 8, 2024

“TAR cloning is used to genetically engineer synthetic viruses with novel properties that may be used for the development of new vaccines.” BUFFALO, NY- January 8, 2024 – A new… read more

Oncotarget

Therapeutically Harnessing Cancer Stem Cell-derived Exosomes

January 3, 2024

“[...] recent significant advances in understanding [...] CSC-Exos have revealed numerous potential applications for diagnosis and treatment.” BUFFALO, NY- January 3, 2024 – A new editorial paper was published in… read more

Figure 9: Effect of GFH009 treatment on CDK9-dependent protein expression in vivo.

Oncotarget

GFH009: A Potent and Highly Selective CDK9 Inhibitor for the Treatment of Hematologic Malignancies

December 27, 2023

“[...] the results of this preclinical investigation program suggest that induction of apoptosis is a key component of GFH009’s anti-tumor mechanism of action [...]” BUFFALO, NY- December 27, 2023 –… read more

Oncotarget

Management of Refractory or Relapsed Classic Hodgkin Lymphoma in Brazil

December 20, 2023

“The management of patients with refractory or relapsed CHL in the Brazilian healthcare setting is constrained [...]” BUFFALO, NY- December 20, 2023 – A new review paper was published in… read more

Figure 1: Trends in the annual numbers of publications.

Oncotarget

Melatonin and Carcinogenesis in Mice

December 18, 2023

“[...] murine models proved to be valuable and, in some cases, indispensable for advancing melatonin applications in oncology [...].” BUFFALO, NY- December 18, 2023 – A new research perspective was… read more

Oncotarget

Cytostatic Persister Cancer Cells: Therapeutic Opportunities and Challenges

December 13, 2023

“[...] we anticipate that heterogeneous persister populations are inevitable in [cancer] treatment.” BUFFALO, NY- December 13, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on December… read more

Oncotarget

Risk Factors for Long-Term Arm Morbidities Following Breast Cancer Treatments: A Systematic Review

December 11, 2023

“This review revealed 29 primary risk factors associated with arm morbidity after breast cancer treatment.” BUFFALO, NY- December 11, 2023 – A new review paper was published in Oncotarget's Volume… read more

Figure 3: Patient examples of inverse correlation of BCMA and FLC changes during course of therapy.

Oncotarget

BCMA+ EV Levels Correlate With Myeloma Response to Belantamab-Mafodotin

December 6, 2023

“Measurement of BCMA-EV can thus help in identifying resistance mechanisms and side effects of BCMA targeted therapies in future studies.” BUFFALO, NY- December 6, 2023 – A new research paper… read more